Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder

Hung, Ching‐I; Liu, Chia-Yih; Yang, Chang‐Hsien; Gan, Shu‐Ting

doi:10.1016/j.jad.2019.08.085

Cited by 25 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Once mastered, they can be transferred also to stressful situations. To make those interventions as good as possible, respiration related variables should find more attention in future studies to ameliorate personalized interventions, as comorbid anxiety in depression is associated with a worse course of the disorder ( Hung et al., 2019 ). Importantly, PD CV and number of bins during sad mood induction seemed to be differentially associated with BAI scores, pointing to the importance of disentangling various respiration parameters and patterns in relation to their impact on anxiety in future studies.…”

Section: Discussionmentioning

confidence: 99%

“…increased suicidal ideation even in the absence of a fully formed comorbid anxiety disorder ( Haberling et al., 2019 ). Further, more comorbid anxiety disorders were related to a poorer outcome in depressed individuals in a 10-year follow-up study ( Hung et al., 2019 ). In sum, there is evidence pointing to a significant role of anxiety in depression, with respiration being one possible important contributing factor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modulation of respiration pattern variability and its relation to anxiety symptoms in remitted recurrent depression

Zamoscik

Schmidt

Timm

et al. 2020

Heliyon

View full text Add to dashboard Cite

Background Depression is related to default mode network (DMN) connectivity and higher respiration pattern variability (RPV). In addition, DMN connectivity and RPV are interrelated and predict a poorer clinical course of depression. The association of RPV and depression might further be boosted by anxiety levels. Aim of the present study was to investigate whether a mindfulness-based training in emotionally challenged remitted depressed participants (rMDD) leads to reduced DMN connectivity and lower RPV, and if RPV interacts with anxiety levels. Methods To challenge participants, sad mood was induced with keywords of personal negative life events in 49 rMDD during fMRI before and after a 4-week mindfulness-based attention training (MBAT) or progressive muscle relaxation. Respiration was measured by means of a built-in respiration belt. Results After both trainings, rMDD showed no significant changes in DMN connectivity. However, MBAT was effective in reducing the RPV which was related to lower anxiety levels especially in high anxious individuals. Conclusions RPV can be influenced by training which may hint to an underlying biological pathway of training effects. Importantly, these effects seem to be associated with anxiety levels. Therefore, respiration focused training might be an important tool assisting the treatment of depression and anxiety.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Modulation of respiration pattern variability and its relation to anxiety symptoms in remitted recurrent depression

Zamoscik

Schmidt

Timm

et al. 2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…Supporting this idea, a comparative analysis of lncRNA expression in patients with other psychiatric illnesses showed that LINC02151 was amongst several lncRNA, which also included LINC02152, LINC02153, NONHSAG045500, NONHSAT034045, NONHSAT142707, that were decreased in PBMCs from patients with MDD and from patients with anxiety disorders [93]. Therefore, decreased levels of these lncRNA could be useful in identifying individuals at risk of comorbid anxiety in MDD, which is associated with poorer prognosis [94]. Interestingly, contrasting the decreased expression seen in MDD and anxiety disorders, the expression level of these lncRNA in schizophrenia is elevated compared to control levels [95], which may provide some evidence that the non-coding transcriptome plays an important role in orchestrating the abnormal expression of psychiatric illness-related genes into a clinically defined illness.…”

Section: Long Non-coding Rna In Mood Disordersmentioning

confidence: 94%

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

Gibbons

Sundram

Dean

2020

ncRNA

View full text Add to dashboard Cite

The similarities between the depressive symptoms of Major Depressive Disorders (MDD) and Bipolar Disorders (BD) suggest these disorders have some commonality in their molecular pathophysiologies, which is not apparent from the risk genes shared between MDD and BD. This is significant, given the growing literature suggesting that changes in non-coding RNA may be important in both MDD and BD, because they are causing dysfunctions in the control of biochemical pathways that are affected in both disorders. Therefore, understanding the changes in non-coding RNA in MDD and BD will lead to a better understanding of how and why these disorders develop. Furthermore, as a significant number of individuals suffering with MDD and BD do not respond to medication, identifying non-coding RNA that are altered by the drugs used to treat these disorders offer the potential to identify biomarkers that could predict medication response. Such biomarkers offer the potential to quickly identify patients who are unlikely to respond to traditional medications so clinicians can refocus treatment strategies to ensure more effective outcomes for the patient. This review will focus on the evidence supporting the involvement of non-coding RNA in MDD and BD and their potential use as biomarkers for treatment response.

show abstract

“…122,123 In addition, comorbid anxiety disorders have been associated with pernicious outcomes in mood disorders, such as lower remission rates of depressive symptoms, increased suicidal ideation, and occupational disabilities. [123][124][125][126] However, treatment of anxiety in mood disorders challenging and therapeutic options are limited, particularly in the light of the safety concerns such as the risk of dependence and cognitive impairment associated with benzodiazepines [127][128][129][130] and the risk of manic switches in the case of antidepressants when prescribed to patients with bipolar disorder. 131,132 Conclusions and Future Directions A strength of this systematic review was the search strategy employed, including a broad range of search terms and databases.…”

Section: Current Evidencementioning

confidence: 99%

Cannabidiol as a Treatment for Mood Disorders: A Systematic Review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique

et al. 2019

View full text Add to dashboard Cite

Objective: To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods: We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, ClinicalTrials.gov , and The Cochrane Central Register of Controlled Trials for studies published up to July 31, 2019. The inclusion criteria were clinical trials, observational studies, or case reports evaluating the effect of pure cannabidiol or cannabidiol mixed with other cannabinoids on mood symptoms related to either mood disorders or other health conditions. The review was reported in accordance with guidelines from Preferred Reporting Items for Systematic reviews and Meta-Analyses protocol. Results: Of the 924 records initially yielded by the search, 16 were included in the final sample. Among them, six were clinical studies that used cannabidiol to treat other health conditions but assessed mood symptoms as an additional outcome. Similarly, four tested cannabidiol blended with Δ-9-tetrahydrocannabinol in the treatment of general health conditions and assessed affective symptoms as secondary outcomes. Two were case reports testing cannabidiol. Four studies were observational studies that evaluated the cannabidiol use and its clinical correlates. However, there were no clinical trials investigating the efficacy of cannabidiol, specifically in mood disorders or assessing affective symptoms as the primary outcome. Although some articles point in the direction of benefits of cannabidiol to treat depressive symptoms, the methodology varied in several aspects and the level of evidence is not enough to support its indication as a treatment for mood disorders. Conclusions: There is a lack of evidence to recommend cannabidiol as a treatment for mood disorders. However, considering the preclinical and clinical evidence related to other diseases, cannabidiol might have a role as a treatment for mood disorders. Therefore, there is an urgent need for well-designed clinical trials investigating the efficacy of cannabidiol in mood disorders.

show abstract

Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder

Cited by 25 publications

References 40 publications

Modulation of respiration pattern variability and its relation to anxiety symptoms in remitted recurrent depression

Modulation of respiration pattern variability and its relation to anxiety symptoms in remitted recurrent depression

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

Cannabidiol as a Treatment for Mood Disorders: A Systematic Review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique

Contact Info

Product

Resources

About